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a b s t r a c t
Objectives: Cognitive impairment is known to occur in bipolar disorder (BD), even in euthymic patients,
with largest effect sizes often seen in Verbal Learning and Memory Tasks (VLT). However, comparisons
between BD Type-I and Type-II have produced inconsistent results partly due to low sample sizes.
Methods: This study compared the performance of 183 BDI with 96 BDII out-patients on an adapted
version of the Rey Verbal Learning Task. Gender, age, years of education, mood scores and age at onset
were all used as covariates. Current medication and a variety of illness variables were also investigated
for potential effects on VLT performance.
Results: BDI patients were signiﬁcantly impaired relative to BDII patients on all ﬁve VLT outcome
measures after controlling for the other variables [Effect Sizes¼ .13–.17]. The impairments seem to be
unrelated to drug treatment and largely unrelated to illness variables, although age of onset affected
performance on three outcome measures and number of episodes of mood elevation affected
performance on one.
Limitations: This study used historical healthy controls. Analysis of potential drug effects was limited by
insufﬁcient participants not being drug free. Cross-sectional nature of the study limited the analysis of
the potential effect of illness variables.
Conclusions: This study replicates earlier ﬁndings of increased verbal learning impairment in BDI
patients relative to BDII in a substantially larger sample. Such performance cannot be wholly explained
by medication effects or illness variables. Thus, the cognitive impairment is likely to reﬂect a phenotypic
difference between bipolar sub-types.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Bipolar disorder (BD) has long been associated with cognitive
impairment even in euthymia (Bearden et al., 2001; Martínez-
Arán et al., 2004a, 2004b; Quraishi and Frangou, 2002; Savitz et al.,
2005). Meta-analyses suggest that most domains of cognition
exhibit some impairment but that the largest deﬁcits tend to be
found in executive control and verbal learning and memory (Bora
et al., 2009; Bourne et al., 2013; Goodwin et al., 2008; Kurtz and
Gerraty, 2009; Mann-Wrobel et al., 2011; Torres et al., 2007). More
recently, studies have attempted to investigate potential differ-
ences in cognitive impairment between bipolar I and bipolar II
patients (Bora et al., 2011; Hsiao et al., 2009; Simonsen et al., 2008;
Solé et al., 2011; Summers et al., 2006; Torrent et al., 2006). Such
studies have produced heterogeneous results.
For example, Torrent et al. (2006) compared the performance of
38 euthymic BDI patients, 33 euthymic BDII patients and 35
healthy controls on a variety of neuropsychological assessments.
The results showed that both patient groups were impaired on all
tests relative to controls but that BDI patients were signiﬁcantly
more impaired than BDII patients on the six outcome measures of
the California Verbal Learning Task (CVLT; Delis et al., 1987). In
contrast, Summers et al. (2006) found that a group of 11 BDII
patients had a verbal memory impairment relative to a group of 25
BDI patients using the Paired Associates Learning Test (PALT;
Warrington, 1996), although a proportion of both BD groups were
non-euthymic at time of testing. Hsiao et al. (2009) compared the
performance of 30 euthymic BDI patients, 37 euthymic BDII
patients and 22 healthy controls on a different battery of neurop-
sychological tests. For some domains, results demonstrated a
similar pattern as Torrent et al. but with respect to verbal memory,
using the Logical Memory and the Verbal Paired Associates
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sub-test from Wechsler Memory Scale, third edition (WMS-III;
Wechsler, 1997), no impairment was found in BDII patients and
the BDI group was impaired relative to both BDII and controls.
Similarly, Simonsen et al. (2008) compared 42 euthymic BDI
patients, 31 euthymic BDII patients and 124 healthy controls on
another neuropsychological test battery and showed that BDII
were not impaired relative to controls on both CVLT and Logical
Memory tests of verbal memory but that BDI were impaired
relative to both BDII and controls.
A systematic review of primary studies of cognition in BDII
(Solé et al., 2011) reﬂected this uncertainty as to whether or not
BDII patients exhibit an impairment in verbal memory relative to
healthy controls and whether BDII patients are more or less
impaired in this domain than BDI patients. Overall, Sole et al.
suggest that BDII patients do exhibit cognitive impairment relative
to controls but that the severity and pattern of impairment differs
from BDI patients. In particular, with respect to verbal learning and
memory, the review reports that approximately half the primary
studies (four out of nine) found that BDII patients performed
worse than healthy controls and that two studies showed BDI
patients were more impaired than BDII patients. These ﬁndings
together suggest that BDII patients may indeed have an inter-
mediate level of impairment relative to healthy controls and BDI
patients.
Finally, Bora et al. (2011) conducted a meta-analysis of primary
studies of cognitive deﬁcits in BDI and BDII patients and healthy
controls. This analysis suggested that both BDI and BDII patients
were impaired relative to controls in all cognitive domains
considered and that overall there was no difference in perfor-
mance between BDI and BDII patients in global cognition or in
most speciﬁc cognitive domains (i.e. processing speed; attention;
planning; and working memory). However, a signiﬁcant difference
was found between BDI and BDII patient in verbal memory with
BDI patients more severely impaired (E.S.¼ .48–.53).
All of the studies and reviews that have considered cognitive
impairment in BDII patients have been interested in describing a
cognitive endophenotype for each subtype that could be the result
of underlying neurobiological differences in the subtypes. How-
ever, the studies have also noted the potential confounding effects
of variables related to illness presentation (such as greater residual
depression in euthymic BDII patients) and treatment (greater use
of antipsychotics in BDI patients).
The current study investigated cognitive performance of BDI
and BDII patients on a verbal learning and memory task in a
relatively large patient sample (N¼279) in an attempt to clarify
the existing literature.
2. Methods
2.1. Study design and sample
Primary data were collected from a cohort of bipolar patients
predominantly residing in Oxfordshire and Buckinghamshire in
the UK who were participants in the OXTEXT research programme.
Demographic and clinical variables were collected for the sample
including: (i) age; (ii) years of education; (iii) current mood; (iv)
age at onset; (v) number of prior episodes of mood elevation (i.e.
manic or hypomanic); (vi) number of prior depressed episodes;
(vii) number of prior manic hospitalisations; (viii) number of prior
depressed hospitalisations; and (ix) drug treatment history. Parti-
cipants undertook a very brief battery consisting of four neurop-
sychological tests, although data presented here are only from an
adapted form of the Rey Verbal Learning Task (Rey, 1941) as this
cognitive domain appears to show the most consistent
inter-subtype differences and also seems to be sensitive to illness
and drug effects (Bourne et al., 2013).
The study received ethical approval from a local National
Research Ethics Service committee (South Central – Oxford A;
REC reference 10/H0604/13) of the UK National Health Service.
Each participant was required to provide written conﬁrmation of
their consent to participate.
2.2. Participants
A total of 279 participants were available for analysis, which
comprised 183 BDI and 96 BDII out-patients. All patients had a
DSM-IV diagnosis of bipolar disorder. The diagnosis was conﬁrmed
by an adaptation of the Mini-International Neuropsychiatric Inter-
view (MINI; Sheehan et al., 1998) and endorsed by a consultant
psychiatrist. Although this study did not recruit a healthy control
comparison group, a post-hoc analysis was undertaken that used
healthy controls taken from two previously published cohorts
(Cavanagh et al., 2002; Clark et al., 2002). This sample of 50
healthy controls had a mean age of 39.4 years.
2.3. Neuropsychological assessment
Five different outcome measures from the verbal learning and
memory task are reported: total score on trials 1 to 5 (Total 1–5);
score on Short Delay (ShortDelay); score on Long Delay (Long-
Delay); score on Recognition (Recognition); score for Recognition
minus score for False Positives (Recog-FP). Three other cognitive
tasks were also used although the data from these other tasks are
not reported here. The other tasks in the brief battery of neurop-
sychological tests were: an emotional face recognition task and an
emotional memory task both taken from the Emotional Test
Battery (Harmer et al., 2009); and a risk reward judgment task
(Abdellaoui et al., 2008). The total duration of the test battery was
less than 90 min.
2.4. Mood assessment
Participants were invited to enrol in the OXTEXT programme
only if their medical notes indicated mood stability over several
months. All participants were registered to submit mood ratings
on a weekly basis by answering text or email prompts from the
True Colours self-monitoring system (www.truecolours.nhs.uk;
Miklowitz et al., 2012).
Weekly depression ratings were captured with the Quick
Inventory of Depressive Symptomology (QIDS; Rush et al., 2003)
and weekly mood elevation ratings with the Altman Self-Rating
Mania scale (ASRM; Altman et al., 1997). Mood ratings used in this
study relate to the participants rating for the week they undertook
the neuropsychological assessment.
Finally, all participants reported were considered to be euthy-
mic by a consultant psychiatrist at time of testing.
2.5. Statistical analyses
Parametric statistical tests were used to compare a variety of
demographic and illness variables between the two bipolar
patients groups. Where appropriate, homogeneity of variance
was checked using Levene's test.
We investigated any diagnosis effect (BDI v BDII) by regressing
diagnosis along with age, gender, years of education, mood (both
depression and mood elevation scores) and age of illness onset
against performance score for each of the ﬁve outcome measures.
Years of education was used as a proxy for pre-morbid IQ as these
variables have been previously shown to be highly correlated
(Bourne et al., 2013). We covaried for variables such as age, gender
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and education as, whilst these variables may not be signiﬁcantly
different on a between group comparison, they are known to affect
neurocognitive performance and can thus reduce the between
group effect size (Bourne et al., 2013).
In order to investigate potential drug effects on subtype
performance differences, patients were coded for six binary (yes/
no) drug status variables: lithium, anticonvulsants, antipsychotics,
antidepressants, benzodiazepines and drug free. Each drug status
variable together with diagnosis, age, gender, years of education,
mood and age of onset were then regressed against performance
score for each of the ﬁve outcome measures except for drug free as
this had less than 10% of patients in one of the drug categories.
Drug data was available for between 82% and 85% of our sample
depending on the drug type.
Similarly, in order to investigate potential effects of illness
severity measures on cognitive performance, number of depressed
episodes, number of episodes of mood elevation, total number of
episodes, number of hospitalisations due to depression, number of
hospitalisations due to mania and total number of hospitalisations
were each ﬁtted separately into the regression model with
diagnosis, age, gender, years of education, mood and age of onset
for each of the ﬁve outcome measures.
Statistical analysis was conducted in SPSS version 21 and all
statistical tests were two-tailed.
3. Results
Tables 1a and 1b show the demographic and illness proﬁles of
the two diagnosis groups. Overall, the groups were well matched
for gender [χ2(1)¼ .19, p¼ .66 ], age [t(277)¼ .41, p¼ .68], years of
education [t(270)¼1.36, p¼ .18], mood elevation score [t(202)
¼ .71, p¼ .48], and age of onset [t(270)¼ .05, p¼ .96]. However,
the groups did differ in depression score [t(203)¼2.83, p¼ .005]
with BDII having a signiﬁcantly higher level of residual depression.
Similarly, the groups differed on the prevalence of antidepressant
treatment [χ2(1)¼5.57, p¼ .018] with 32% of BDI patients and 48%
of BDII patients on antidepressants. There was a trend for a
difference in prevalence of Lithium treatment [χ2(1)¼3.68,
p¼ .055] with BDI patients more likely to be taking lithium (37%
BDI vs 25% BDII). However, the groups did not differ on prevalence
of antipsychotic treatment [χ2(1)¼2.06, p¼ .15], anticonvulsant
treatment [χ2(1)¼ .20, p¼ .67], benzodiazepine treatment
[χ2(1)¼ .003, p¼ .96], or drug free status [χ2(1)¼ .012, p¼ .91].
The groups did not differ on number of episodes of mood
elevation [t(238)¼1.5, p¼ .13] but did on number of depressive
episodes [t(241)¼2.31, p¼ .02] and total episodes [t(235)¼2.27,
p¼ .03], with BDII patients having more depressive episodes and
consequently more total episodes. In contrast, the groups did not
differ on number of depressive hospitalisations [t(266)¼1.3,
p¼ .18]. By deﬁnition, none of the BDII patients had any manic
hospitalisations and because the BDI patients had signiﬁcantly
more manic hospitalisations than zero [t(267)¼8.05, po .001],
total hospitalisations were also more common for BDI [t(264)¼
4.9, po .001].
3.1. Diagnosis effects
The results of the regressions comparing performance of the
BDI and BDII groups on the ﬁve outcome measures whilst also
accounting for the effects of age, gender, years of education, mood,
and age of onset are shown in Table 2.
The BDII group performed signiﬁcantly better than the BDI
group on all ﬁve outcome measures with relatively small but
consistent effect sizes (.13–.17).
The covariant age of onset signiﬁcantly predicted performance
on three of the ﬁve VLT measures [Total 1–5: β¼ .19, t¼2.70,
p¼ .008; Long Delay: β¼ .17, t¼2.36, p¼ .019; Recognition:
Table 1a
Demographic and illness variables for BDI and BDII diagnosis groups.
N¼279 BD-I (N¼183) BD-II (N¼96) Comparison test
M (SD) M (SD) t p
Age (N¼279) 41.7 (12.9) 41.0 (14.5) .42 .71
Years of education (N¼272) 15.7 (3.5) 15.0 (4.1) 1.36 .18
Mood elevation score (N¼204) 3.58 (4.4) 4.10 (5.4) .71 .48
Depression score (N¼205) 8.79 (5.6) 11.25 (6.1) 2.83 .005
Age at onset (N¼272) 20.1 (9.7) 20.0 (10.1) .05 .96
No. depressive episodes (N¼205) 19.0 (24.4) 27.7 (30.1) 2.31 .022
No. manic/hypomanic episodes (N¼204) 15.5 (21.5) 20.1 (23.8) 1.52 .13
Total episodes (N¼237) 34.1 (39.4) 48.0 (47.7) 2.27 .025
No. depressive hospitalisations (N¼268) 1.4 (2.4) 1.0 (1.9) 1.34 .18
No. manic hospitalisations (N¼269) 1.5 (2.4) .0 (.0) 8.05 o .001
Total hospitalisations (N¼266) 2.9 (3.6) 1.2 (2.1) 4.93 o .001
Table 1b
Gender and drug status for BDI and BDII diagnosis groups.
N¼279 BD-I (N¼183) BD-II (N¼96) Comparison test
Count þ() Count þ() χ2 p
Female (Male) 123 (60) 67 (29) .19 .66
Lithium (N¼234) 55 (94 free) 21 (64 free) 3.68 .055
Anticonvulsants (N¼233) 63 (86 free) 33 (51 free) .20 .66
Antipsychotics (N¼235) 74 (77 free) 33 (51 free) 2.06 .15
Antidepressants (N¼231) 47 (100 free) 40 (44 free) 5.57 .018
Benzodiazepines (N¼238) 22 (131 free) 12 (73 free) .01 .91
Drug free (N¼233) 15 (133 any drug) 9 (76 any drug) .01 .96
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β¼ .22, t¼2.84, p¼ .005] with early age of onset associated with
poorer performance.
3.2. Drug effects
The regression analysis comparing the performance of the
patients on Lithium and those Lithium free on the ﬁve outcome
measures whilst also accounting for the effects of diagnosis, age,
gender, years of education, mood, and age of onset suggested that
lithium did not affect any of the outcome measures (p¼ .25  .72
for all lithium β coefﬁcients). Similarly, antidepressants showed no
effect on performance (given effects of diagnosis, age, gender,
years of education, mood, and age of onset) on any of the ﬁve
outcome measures (p¼ .27–.92 for all antidepressant β coefﬁ-
cients) and anticonvulsants also showed no effect on performance
(given effects of diagnosis, age, gender, years of education, mood,
and age of onset) on any of the ﬁve outcome measures
(p¼ .66 .97 for all anticonvulsant β coefﬁcients). Finally, antipsy-
chotics showed no effect on performance (given effects of diag-
nosis, age, gender, years of education, mood, and age of onset) on
any of the ﬁve outcome measures (p¼ .18–.55 for all β antipsycho-
tic coefﬁcients). Benzodiazepines showed an effect on perfor-
mance for Total 1–5 scores [β¼ .14; t¼2.13, p¼ .035] (given
effects of diagnosis, age, gender, years of education, mood, and
age of onset) with taking benzodiazepines being related to poorer
performance but had no effect on any of the other performance
measures (p¼ .26–.33 for all other benzodiazepine β coefﬁcients).
3.3. Effect of illness variables
The analysis considering the effect of illness variables on VLT
performance suggests that most of the variables considered did
not affect any of the ﬁve outcome measures after accounting for
the effects of diagnosis, age, gender, years of education, mood, and
age of onset [number of depressive episodes, p¼ .35  .78 for β
values across the ﬁve VLT measures; total episodes, p¼ .15–.92 for
all β values; number of depressive hospitalisations, p¼ .11–.92 for
all β values; number of manic hospitalisations, p¼ .22–.96 for all β
values; total hospitalisations, p¼ .11–.95 for all β values]. Number
of episodes of elevated mood was related to performance on
Recog-FP [β¼ .21; t¼2.63, p¼ .009] with more episodes predicting
poorer performance as a result of increased false positives. How-
ever, number of episodes of elevated mood was not related to
performance on any of the other four outcome measures
[p¼ .21–.93 for all other β values].
4. Discussion
The analysis comparing this sample of BDI and BDII patients
suggests that BDI patients are more severely impaired on all ﬁve
VLT outcome measures after accounting for the effects of age,
gender, years of education, mood (both depression and mania
scores) and age of illness onset. This ﬁnding is consistent with the
results of several primary studies (Hsiao et al., 2009; Simonsen
et al., 2008; Torrent et al., 2006) and a meta-analysis (Bora et al.,
2011) with all suggesting that BDII patients outperform BDI
patients on verbal learning and memory tests. However, it should
be noted that our effect sizes (.13–.17) were considerably lower
than those previously found (.48–.53). This was probably due to
our partialling-out the effect of age, gender, years of education,
mood and age of illness onset on performance.
Indeed, our results are opposite only to that of Summers et al.
(2006) where a different verbal memory test was used. Where the
literature is less consistent is in comparing the performance of
BDII patient with healthy controls; some studies suggest BDII
performance is comparable to controls (Hsiao et al., 2009; Torrent
et al., 2006) whilst others ﬁnd BDII patients intermediately
impaired relative to both BDI patients and controls (Simonsen
et al., 2008; Torrent et al., 2006). As our study had no control
group we were unable to directly address this issue. However, we
undertook a post-hoc comparison of our BDII patients with healthy
controls taken from two previous studies of VLT performance in
bipolar patients recruited from the same geographical area
(Cavanagh et al., 2002; Clark et al., 2002) which used similar
duration of test battery. This comparison suggested that our BDII
group had an intermediate level of impairment relative to our BDI
group and healthy controls. Speciﬁcally, our BDII patients were
signiﬁcantly impaired relative to controls after controlling for age
and gender on Total1–5 [E.S.¼ .15; p¼ .045] but performed
comparably to controls on the other VLT outcome measures
[ShortDelay: E.S.¼ .09, p¼ .21; LongDelay: E.S.¼ .10, p¼ .23; Recog.:
E.S.¼ .05, p¼ .55]. These ﬁndings are consistent with the mixed
picture of prior studies suggesting BDII patients have either an
intermediate level of impairment relative to controls or no
impairment relative to controls.
Any account of a performance differential between BDI and
BDII patients must at this stage be purely speculative. However,
two main potential explanations arise. First, BDII is often con-
ceptualised as a ‘milder’ form of BDI: some neurological impair-
ments (relative to controls) appear common to the two sub-types,
such as right lateral ventricular enlargements (McDonald et al.,
2004) and volume reductions in prefrontal areas (Kempton et al.,
2008), especially ventromedial prefrontal areas (Ha et al., 2009),
whilst other abnormalities seem present only in BDI patients, such
as volume reductions in frontal and parahippocampal cortices (Ha
et al., 2009). Indeed, a current mega-analysis (Hibar et al.,
Submitted) of MRI structural scans from 885 BDI patients, 329
BDII patients and 2613 controls suggests that BDI patients exhibit
volume reductions in amygdala, hippocampus, thalamus and
ventricular enlargement compared to controls. However, BDII
patients showed amygdala, hippocampal and ventricular volumes
in between those of controls and BDII patients although not
signiﬁcantly different from either group. It is this intermediate
performance of BDII patients relative to BDI patients and controls
that we have identiﬁed in the verbal learning and memory task.
Furthermore, this task involves the hippocampus and left frontal
areas associated with language as shown to be impaired in bipolar
disorder by neuroimaging studies. Alternatively, intermediate
performance of BDII patients may be due to differences in illness
progression. By deﬁnition, BDII patients do not experience true
manic episodes (although our sample shows similar numbers of
hypomanic episodes in BDII patients compared to manic episodes
in BDI) and cognitive impairment has been shown to be correlated
with number of manic episodes (Bourne et al., 2013) especially in
verbal learning and memory tasks. Thus, initially both bipolar sub-
types may have similar levels of verbal learning and memory
performance but that BDI patients suffer further declines in
performance, or at least steeper declines relative to BDII, following
each manic episode. Finally, it should be acknowledged that these
Table 2
Comparison of BDI and BDII VLT performance accounting for age, gender, years of
education, mood, and age of onset across the ﬁve outcome measures.
BD-I BD-II
(N¼279) M (SD) M (SD) t p E.S.
Total 1–5 56.8 (11.2) 58.4 (10.0) 2.16 .032 .14
Short Delay 12.1 (3.0) 12.6 (2.9) 2.01 .046 .13
Long Delay 12.0 (3.3) 12.7 (2.9) 2.05 .042 .14
Recognition 15.0 (1.5) 15.1 (1.4) 2.00 .047 .15
Recog-FP 13.6 (2.9) 14.2 (1.9) 2.36 .020 .17
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two speculations are not mutually exclusive and may be additive
or interactive.
With respect to possible drug effects on performance, our
analysis found no basis for the potential claims that lithium may
improve cognitive performance via reduced oxidative stress (Mora
et al., 2012; Shao et al., 2005; Tan et al., 2011) nor that anti-
psychotics may reduce performance as some studies have sug-
gested (Donaldson et al., 2003; Jamrozinski et al., 2009). We did
ﬁnd evidence that benzodiazepines might reduce cognitive per-
formance but only for one of the ﬁve outcome measures (Total 1–
5). Together, these ﬁndings are consistent with the recent large
IPDMA study (Bourne et al., 2013) that showed that only anti-
psychotic drugs had any signiﬁcant effect on cognitive perfor-
mance and even then only for one of 11 outcome measures
considered (albeit within the verbal learning and memory
domain).
Although some studies have suggested that illness variables
may be predictive of cognitive decline (Robinson and Ferrier,
2006), our ﬁndings showed mixed support for this. Age of onset
signiﬁcantly predicted performance for three of the ﬁve outcome
measures with a lower age of onset being related to worse
performance and number of manic episodes being predictive of
performance for one outcome measure with more manic episodes
being related to worse performance. The ﬁnding of a limited effect
of age of onset on cognitive performance provides some support
for the notion of neuroprogression and clinical staging in bipolar
disorder (Berk et al., 2007, 2011). However, for our data to fully
support a neuroprogressive model, relationships between illness
factors such as illness duration and number of episodes should
have been found more widely (Gama et al., 2013). One explanation
for a lack of such relationships may be the presence of co-
regressors such as age of onset that are highly correlated with
key staging/progression variables. Indeed, as noted elsewhere
(Bourne et al., 2013), illness progression effects may be difﬁcult
to detect, especially in cross-sectional studies and are only likely to
result from adequately powered longitudinal studies potentially
commencing in pre-clinical, “at-risk” samples. However, the ﬁnd-
ing of a relationship between manic episodes and more false
positives in the recognition task may hint at neuroprogression and
related kindling effects (Post, 2007). Clinically, manic episodes are
related to increases in impulsivity (Strakowski et al., 2010; Swann
et al., 2008) and so individuals exposed to greater numbers of
manic episodes may, over time, develop underlying neuronal
substrates that promote impulsive behaviours including increased
false detection of distractor items in a recognition test (Kockler
and Stanford, 2008; Swann et al., 2003).
4.1. Limitations
As with any clinical study, a major potential limitation is
sampling bias. However, it is noted that the BDI and BDII patient
groups presented here were well matched for a variety of
confounding variables including age, gender, years of education,
mood elevation score, and age of onset. These variables were still
used as co-regressors as they are known to affect cognitive
performance and we wished to estimate the effect size of sub-
diagnosis free from such other effects. Unfortunately, the patient
groups were not matched for depression mood score (BDII patients
had higher residual mood) or prevalence of lithium medication
and antipsychotics medication (BDI patients were more frequently
taking both medications). However, depression mood score was
also used as a co-regressor in all sub-type analyses and sub-type
diagnosis was also included in the drug effect analysis to attempt
to control for these confounds. It is also likely that these group
differences were confounds by indication and represent under-
lying differences in symptom presentation and treatment between
the two sub-types rather than simple sampling bias. Similarly, the
groups were well matched on two further illness variables
(number of episodes of mood elevation and number of depressive
hospitalisations) but neither on number of depressive episodes
and hence number of total episodes (BDII higher for both) nor on
the number of manic hospitalisations and hence number of total
hospitalisations (BDI higher for both). Again these are considered
to be confounds by indication rather than sampling bias per se.
Another limitation of this study is the lack of a speciﬁcally
recruited healthy control group. However, the post-hoc analysis
using healthy controls from two prior which used a similar
duration of test battery studies and recruited from the same
geographical area (Cavanagh et al., 2002; Clark et al., 2002) was
intended to mitigate this limitation.
In any event, overall this study ﬁnds evidence of signiﬁcantly
greater deﬁcit in BDI relative to BDII patients in all ﬁve verbal
learning and memory outcome measures. We found no obvious
effects of medication and some suggestion that illness variables
such as age of onset and number of manic episodes may track
cognitive deﬁcits in this domain.
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